Emergent BioSolutions | EBS - 市值



金融业
股票价格
USD
资产
USD 1.82B
现金及等价物
USD 111.7M
销售成本
USD 381.2M
流动资产
USD 679.5M
流动负债
USD 651.3M
债务
USD 903.2M
股息收益率
0
EBIT
USD -148.1M
EBITDA
USD -113.5M
员工
1.6K
EPS每股收益
USD -0.77
股本和储备
USD 649.3M
销售毛利
USD 10M
债务利息支出
USD 17.9M
贷款资金
USD 446.5M
市值
USD 332.5M
净收入
USD -261.3M
营业费用
USD 555.9M
营业利润
USD -218M
普通股股本
USD 100K
PE价格收益
14.4
税前利润
USD -130.8M
销售收入
USD 276.6M
销售和管理费用
USD 182.8M
股票
USD 328.9M
贸易债权人
USD 112.2M
应收帐款人
USD 290.1M


市值 更改 日
Acadia Pharmaceuticals USD 4.33B 537M 2026-06
Akebia Therapeutics USD 427M 297M 2025-12
ALKERMES USD 8.73B 2.85B 2026-06
Alnylam Pharmaceuticals USD 40.19B 3.96B 2026-06
Amarin USD 290M 51M 2025-12
ANI Pharmaceuticals USD 1.88B 133M 2026-06
BioMarin Pharmaceutical USD 11.06B 196M 2026-06
Coherus Biosciences USD 172M 19M 2025-12
Emergent BioSolutions USD 125M 51M 2023-12
Exelixis USD 13.54B 2.65B 2026-06
Glaxosmithkline GBP 109.29B 9.36B 2026-03
Heron Therapeutics USD 238M 7M 2025-12
Ionis Pharmaceuticals USD 13.1B 642M 2026-06
Lexicon Pharmaceuticals USD 418M 73M 2025-12
Lonza CHF 39.68B 980.61M 2025-06
Merck USD 317.37B 20.27B 2026-06
Nektar Therapeutics USD 2.12B 1.26B 2026-03
Neurocrine Biosciences USD 16.95B 3.7B 2026-06
Pacira USD 998M 83M 2026-06
Pfizer USD 138.44B 15.37B 2026-06
Sanofi EUR 91.15B 9.12B 2026-06
Sarepta Therapeutics USD 1.9B 388M 2026-06
United Therapeutics USD 23B 2.19B 2026-06
Vanda Pharmaceuticals USD 279M 6M 2024-12